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Abstract 
A simple modification of DNA aptamer with polyethylene glycol (PEG) based on metal 
coordination was developed. N,N-bis(carboxymethyl)-L-lysine (NTA) of a metal 
chalate residue was chemically introduced to one terminal of PEG. The NTA-introduced 
PEG (PEG-NTA) chelated Cu2+ ions to form a Cu2+-chelated PEG (PEG-Cu). When the 
Cu2+-chelated PEG was mixed with a DNA aptamer of anti-tumor activity (AS1411) in 
aqueous solution, the complex of PEG-Cu and AS1411 based on metal coordination was 
formed. The complex inhibited in vitro tumor growth in a dose-dependent manner. Body 
distribution study with tumor-bearing mice revealed that the PEG-Cu-AS1411 
complexes intravenously injected showed a significant longer life-period in the blood 
circulation and 1.5-2.0 fold higher accumulation in the tumor tissue than free AS1411. 
Intravenous injection of complexes suppressed the in vivo growth of tumor mass to a 
significantly great extent compared with that of free AS1411. The Cu2+-coordinated 
PEG modification is a simple and promising method to enhance the tumor accumulation 
of aptamer, resulting in the augmented anti-tumor effect. 
Keywords 
DNA aptamer; polyethylene glycol; metal coordination; tumor targeting; anti-tumor 
effect 
Introduction 
Drug Delivery System (DDS) is a technology available to enhance the 
therapeutic effect of drugs. As one DDS technology, chemical modification of drugs 
with various water-soluble polymers has been attempted [1, 2]. Polyethyleneglycol 
(PEG) modification of drugs, so-called PEGylation, has been widely carried out to 
improve their solubility and in vivo stability [3, 4]. PEGylation prevents the rapid renal 
clearance of drugs and their receptor-mediated uptake by the reticuloendothelial system, 
resulting in prolonging their in vivo half-time. In addition, passive tumor targeting of 
drugs can be achieved by their PEGylation. This can be explained by the enhanced 
permeability and retention (EPR) effect [5, 6], which is mainly governed by two factors: 
the disorganized pathology of angiogenic tumor vasculature with its discontinuous 
endothelium, leading to hyperpermeability to circulating polymers, and the lack of 
effective tumor lymphatic drainage, which leads to the consequent polymers 
accumulation. Based on this anatomical feature, it is well recognized that 
long-circulating polymers are passively accumulated in the tumor tissue. Such an 
enhanced accumulation to the site of action enables a drug to reduce the dose necessary 
for their therapeutic effect and consequently to minimize the side-effects caused by the 
high-dose and repeated administrations. 
However, this PEGylation method needs the chemical conjugation of PEG with drugs. 
The chemical conjugation of drugs is sometimes of poor reproducibility and often 
causes the activity loss. Therefore, it is necessary to develop a new and simple 
conjugation method without using chemical coupling. We have developed a new 
conjugation method of drugs (protein or nucleic acid) and polymers (dextran, pullulan 
or PEG) based on metal coordination [7-10]. The objective of this paper is to prepare 
the drug conjugation with PEG based on the metal coordination. In this study, 
N,N-bis(carboxymethyl)-L-lysine (NTA) was used as the chelate residue which binds 
several types of metal ions such as Ca2+, Mg2+, Fe2+, Ni2+ or Zn2+. The NTA has a low 
toxicity [11] and had been widely used for the biomedical application; ligand for the 
immobilized metal affinity chromatography (IMAC) which enables to purify a protein 
[12], oriented surface modification of substrate with the protein [13, 14], and sustained 
release of protein from the hydrogel [15]. Additionally, the NTA has one amino group, 
which is suitable to the chemical-modification with ease.       
A DNA aptamer, AS1411 was used as the drug. AS1411 is a 26-mer 
guanosine-rich oligonucleotide (GRO) and inhibits the growth of tumor cells in vitro 
and human tumor xenograft in vivo [16-18]. AS1411 is known to form stable G-quartets 
structures and bind to nucleorin with a high affinity. Nucleorin is a multifunctional 
protein and its functions are ribosome biogenesis, signal transduction, DNA replication, 
protein trafficking, and mRNA stabilization [19, 20]. Nucleorin is present in the nucleus 
of normal cells. However, in tumor cells, the nucleorin expresses on the cell surface. 
Based on that, AS1411 has a specific affinity to the tumor cell, not to the normal cell. 
The AS1411 internalized is transferred to the nucleus, followed by the inhibition of 
DNA replication and induction of S-Phase cell cycle arrest. It is reported that AS1411 
induces the transcription inhibition of nuclear factor-B (NF-B) [20] and 
destabilization of Bcl-2 mRNA [21], resulting in showing an anti-tumor function. 
In this paper, the nitrilotriacetic acid (NTA) of a chelating residue was 
chemically introduced to the terminal of PEG. The NTA-introduced PEG was 
conjugated to the AS1411 of DNA aptamer through Cu2+ coordination. In vitro and in 
vivo anti-tumor activity or tumor accumulation of PEG-AS1411 complexes with Cu2+ 
coordination was assessed. We physicochemically examined the Cu2+-coordinated 
complexation between the NTA-introduced PEG and AS1411. 
 
Materials and Methods 
2.1. Materials 
 PEG with methoxy and N-hydroxy succinimide (NHS) group terminals 
(PEG-NHS, the weight-averaged molecular weight (Mw) 5,000 (linear) and 40,000 
(branch, one terminal group)) was purchased from NOF Co., Tokyo, Japan. 
N,N-bis(carboxymethyl)-L-lysine (NTA) was purchased from Fluka Ltd., Tokyo, Japan. 
AS1411 (5’-GGTGGTGGTGGTTGTGGTGGTGGTGG-3’) and AS1411-NH2 
(5’-Amino Modifier C6-GGTGGTGGTGGTTGTGGTGGTGGTGG-3’) were purchased 
from Integrated DNA technologies, Inc., Coralville, IA.  
 
2.2. NTA introduction to PEG 
PEG-NHS with the Mw 5,000 or 40,000 was dissolved in 100 ml of dehydrated 
dimethyl sulfoxide (DMSO) at a final concentration of 1 mM, and then NTA was added to 
give a final concentration of 10 mM (showed scheme 1). The solution was agitated at 37 °C 
for 24 hr to allow NTA to couple to the NHS residue of PEG-NHS, and then dialyze against 
ultra-pure double-distilled water (DDW) for 3 days with a dialysis membrane 
(Spectra/Por® dialysis membrane MWCO 3,500, Spectrumlabs.com). The dialyzed 
solution was freeze-dried to obtain a NTA-introduced PEG (PEG-NTA). To characterize the 
PEG-NTA prepared, 1H-NMR measurement was performed in D2O including 0.05 wt% 
3-(trimethylsilyl)-propionic-2,2,3,3-d4 acid, sodium salt on the NMR apparatus (JNM-EX, 
JEOL). The percent of NTA introduced was determined by the integration ratio of the 
CH3O- peak ( =3.4 ppm) from PEG to the -C-CH2-C- ( =1.6 ppm) peak from NTA. 
 
2.3. Preparation and characterization of Cu2+-chelated PEG-NTA 
PEG-NTA with the Mw 5,000 or 40,000 was dissolved in 1 ml of DDW at a 
final concentration of 10 mM. Then, 1 ml of 10, 30, 100, and 500 mM CuCl2 aqueous 
solution was added to the PEG-NTA solution. Mixing molar ratio of Cu2+ ions to 
PEG-NTA was 1, 3, 10 or 50. The mixture was applied to a gel permeation 
chromatographic column (PD-10) (Sephadex G-25, column lengh = 10 cm, GE 
healthcare) with the elution solution of 10 ml DDW, and 0.5 ml of every fraction was 
collected. The concentration of Cu2+ ions in each fraction was determined by UV-Vis 
spectroscopy (800 nm, DU 800 UV/visible spectrophotometer, Beckman coulter). The 
concentration of Cu2+ ions was determined by use of the calibration curve which is 
prepared by CuCl2 at pre-determined concentration. The number of Cu2+ ions chelated 
per one PEG-NTA molecule was calculated from the molar ratio of Cu2+ ions to 
PEG-NTA in high-molecular weight fraction.  
 
2.4. Characterization of Cu2+ coordination to AS1411 
Aqueous solution of CuCl2 (1 ml, 100 mM) was applied to a chelating column 
(HiTrapTM Chelating HP, GE Healthcare). After washed the column with 
phosphate-buffered saline solution (PBS, pH 7.4) to prepare a Cu2+ ions-immobilized 
column, 1 ml of AS1411 aqueous solution (1 M) was applied. Additional 5 ml of PBS 
was applied to the column, and then the eluted solution (1 ml) was collected. Next, PBS 
containing 50 mM imidazole was added while 1 ml of eluted solution was collected. 
Imidazole is a strong ligand to Cu2+ ions, and inhibits the coordinate bond of AS1411 to 
Cu2+ ions. The eluted solution was determined by UV-Vis spectroscopy (260 nm) to 
evaluate the concentration of AS1411. On the other hand, the mouse serum is added 
after AS1411 addition to the Cu2+-immobilized column and incubated for various time 
periods. Then the same procedure was performed as described above. The concentration 
AS1411 eluted before imidazole addition was measured to evaluate the stability of 
Cu2+-coordinated AS1411.   
 
2.5. Preparation and characterization of PEG-Cu-AS1411 complexes 
PEG-NTA with the Mw 5,000 or 40,000 with Cu2+ coordination (PEG-Cu) was 
dissolved in PBS, and the solution was mixed with PBS containing AS1411, followed by 
leaving for 15 min at room temperature to obtain 1 ml of solution containing complexes 
of PEG-Cu and AS1411 based on Cu2+ coordination. The final concentration of PEG-Cu 
was 60, 300 or 1200 M while that of AS1411 was 60 M. The mixing molar ratio of 
PEG-Cu to AS1411 was 1, 5 or 20. Following 1 ml of solution containing complexes was 
applied to an anion-exchange chromatographic column (HiTrapTM DEAE FF, GE 
Healthcare Amersham Biosciences KK, Tokyo, Japan), the eluted solution was collected 
by applying 3 ml of phosphate-citrate buffer (0.1 M, pH 7.0). Then, phosphate-citrate 
buffer containing 0.3, 0.35, 0.4, 0.45, 0.5, 0.6, 0.7, and 1 M of NaCl was applied and the 
eluted solution was collected. The concentrations of PEG-Cu and AS1411 in the eluted 
solution were determined by high performance liquid chromatography (HPLC, LC-8020 
model-Ⅱ, Tosoh, Tokyo, Japan) and UV-Vis spectroscopy, respectively. For the HPLC 
measurement, the samples were applied to HPLC equipped G3000SWXL columns at 
37 ℃ at a flow rate of 0.5 ml/min in 0.02 M phosphate-buffered solution pH 7.4 
containing 0.3 M NaCl. The concentration of PEG-Cu was determined by use of the 
calibration curve. The concentration of PEG-Cu molecules complexed was calculated by 
subtracting the concentrations of PEG-Cu initially added from that of eluted. In the same 
way, the concentration of AS1411 complexed can be calculated. The number of PEG-Cu 
conjugated per one AS1411 molecule was calculated from by dividing the concentration 
of PEG-Cu complexed by that of AS1411. 
 
2.6. In vitro anti-tumor activity of PEG-Cu-AS1411 complexes 
Human lung cancer A549 cells were grown in Dulbecco’s Modified Eagle 
Medium (DMEM, Sigma-Aldrich, St. Louis, MO) supplemented with 10 % 
heat-inactivated (55 ℃ for 30 min) fetal bovine serum, and 0.1 % penicillin and 
streptomycin at 37 ℃ and 5 % CO2-air atomosphere. A549 cells grown were seeded 
into each well of 96 multi-well cell culture plate (#3595, Corning Inc., Corning NY) at a 
density of 5 × 103 cells/well, and then 24 hr later PEG-Cu-AS1411 complexes were 
added at the final AS1411concentrations of 1, 3, 5, 7.5, and 10 M (AS1411 amount; 
0.1, 0.3, 0.5, 0.75, and 1.0 nmol, respectively) and at the mixing molar ratio of PEG-Cu 
to AS1411 of 0, 1, 5, and 20. After 6 days culture, the medium was changed (100 
l/well) and Cell Count Reagent SF (Nacalai Tesque, Inc., Kyoto, Japan) was added (10 
l/well). After 1 hr culture, the absorbance which reflect  of each well at 450 nm was 
determined by a microplate reader (VERSA max, Molecular Devices Japan Co., Osaka, 
Japan) to evaluate the number of cells grown.  
 
2.7. Tumor accumulation of PEG-Cu-AS1411 complexes  
A549 cells (5 × 106 cells) suspended in 100 l of PBS were inoculated into the 
left flank of BALB/c nude mice (6-week-old female, body weight = 18 g, Shimizu 
Laboratory Supplies Co. Ltd., Kyoto, Japan). When the tumor mass grew to 5-7 mm in 
average diameter about 10 days after inoculation, the tumor-bearing mice were used for 
the following in vivo experiments.  
The tumor accumulation of AS1411 was evaluated by the conventional 
fluorescent and radioisotope tracing methods. For the radiotracing, AS1411 was 125I 
radioiodinated through the pyrimidine iodination in the presence of TlCl3 [22]. Briefly, 
5 l of Na125I (740 MBq/ml in 0.1 M NaOH aqueous solution, NEN Reserch Products) 
solution was added into 20 l of 0.3 mM Na2SO3 solution and left for 15 min in room 
temperature. Then, 100 l of 0.1 M sodium acetate-40 mM acetic acid (pH 5.0) 
containing 10 mg/ml AS1411 solution was added into 100 l of 4 mM TlCl3. AS1411 
solution was added into Na125I solution, and mixture was heated (60 ℃ for 50 min). 
Then, 0.1 ml of 0.1 M Na2SO3 and 0.9 ml of 50 mM tris buffer (pH 7) containing 0.1 M 
NaCl and 1 mM EDTA were added into the heated mixture. After heating at 60 ℃ for 
30 min, the resulting mixture was passed through a PD-10 column to remove uncoupled 
125I molecules to obtain an aqueous solution of 125I-labeled AS1411 (AS1411-125I). The 
concentration of AS1411-125I was determined with UV-Vis spectroscopy (260 nm).  
Tumor-bearing mice received the intravenous injection of 100 l of 
AS1411-125I alone or PEG-Cu-AS1411-125I complex. The amount of AS1411-125I 
injected was 50 g per mouse and the mixing molar ratio of PEG-Cu to AS1411-125I 
was 20. The tumor tissue and blood samples were taken out 1, 6, and 24 hr later and the 
radioactivity was measured by a gamma counter (ARC-301B, Aloka Co. Ltd., Tokyo, 
Japan). From the radioactivity and weight of the tumor tissue, the amount of 
accumulated AS1411-125I (g /g tumor) was calculated. On the other hand, from the 
blood radioactivity, the amount of AS1411-125I remaining in the blood circulation was 
calculated under the assumption that the total blood weight in a mouse corresponds to 
8% of its body weight and the blood density is 1.0. Each experiment group consists of 3 
mice. For the fluorescent tracing, 800 l of 0.1 M sodium carbonate and sodium 
biscarbonate-buffered solution (pH 9.3) containing 2 mg of AS1411-NH2 was 
fluorescently labeled with Cy 5.5 (Cy 5.5 mono reactive dye pack, GE healthcare 
Amersham Biosciences KK, Tokyo, Japan) according to the manufacturer’s instructions. 
Tumor-bearing mice received the intravenous injection of 100 l of Cy 5.5-labeled 
AS1411 (AS1411-Cy 5.5) alone or PEG-Cu-AS1411-Cy 5.5 complex. The amount of 
AS1411 injected was 50 g per mouse and the mixing molar ratio of PEG-Cu to 
AS1411-Cy 5.5 was 20. The in vivo fluorescence imaging was performed by LAS4000 
(FUJI FILM Co. Ltd., Kanagawa, Japan) 1, 6, 24, and 48 hours after injection. From the 
fluorescent intensity at the tumor site, the mean gray value was recorded as photons per 
millimeter squared and was normalized by the autofluorescence to evaluate the time 
profile of tumor accumulation of AS1411. Each experiment group consists of 3 mice. 
 
2.8. In vivo anti-tumor effect of PEG-Cu-AS1411 complexes  
To evaluate the in vivo anti-tumor effect of PEG-Cu-AS1411 complexes, mice 
with the similar tumor tissue size (about 5-7 mmin diameter) received the intravenous 
injection of 200 l of AS1411 alone or PEG-Cu-AS1411 complex every 3 days. The 
amount of AS1411 injected was 100 g per mouse at each time and the mixing molar 
ratios of PEG-Cu to AS1411 was 20. The length of long axis (a) and short axis of tumor 
mass (b) were periodically measured and the tumor volume (V) was calculated 
according to the formula of V=1/2×a×b2. On the 42 day, the tumor tissue was taken out 
to measure the wet weight. Each experiment group consists of 5 mice. 
 
2.9. Statistical analysis 
All the data were statistically analyzed by Post hocs Bonferroni /Dunn and expressed as 
the mean +/- the standard deviation of the mean. Statistical significance was accepted at 
p < 0.05. 
 
Results 
3.1. Preparation and characterization of PEG-NTA 
Figure 1 shows the preparation scheme of PEG-NTA and the 1H NMR spectra 
of NTA, PEG-NHS, and PEG-NTA. The NTA and PEG-NTA samples exhibited peaks 
attributed to C-CH2-C at 1.15-2.05 ppm, in contrast to the PEG-NHS. The percent NTA 
introduced to PEG with the Mws of 5,000 and 40,000 was 92.5 and 88.5 %, 
respectively. 
 
3.2. Metal chelation of PEG-NTA 
Figure 2 shows the gel permeation chromatographic patterns of PEG-NTA and 
PEG-NHS after mixing with Cu2+ ions. In the gel permeation chromatography, 
substances with high molecular weights (> 5,000) and low molecular weights were 
eluted in the flow volume ranges of 2-4 and 4-10 ml, respectively. For the mixture of 
PEG-NTA and Cu2+ ions, both the high-molecular and low-molecular weight peaks 
were detected. On the contrary, only the low-molecular weight peak was observed for 
the mixed PEG-NHS and Cu2+ ions. The amount of Cu2+ ions in the high-molecular 
weight peak was similar, irrespective of the mixing molar ratio of PEG-NTA to Cu2+ 
ions. One PEG-NTA molecule chelated about one Cu2+ ions for any mixed sample of 
Cu2+ ions and PEG-NTA with the molecular weight of 5,000 (Figure 2B). In the case of 
PEG-NTA with the molecular weight of 40,000, the molar ratio of Cu2+  ions to 
PEG-NTA increased with an increase in the amount of Cu2+ initially added (Figure 2D). 
 
3.3. Characterization of PEG-Cu-AS1411 complexes  
Figure 3 shows the elution pattern of AS1411 from the Cu2+-chelated column 
in the absence or presence of serum. Most of AS1411 applied was eluted by the addition 
of imidazole (the flow volume was 6-10 ml) in the absence of serum. This means that 
the AS1411 bind to Cu2+ ions. On the other hand, when incubated with mouse serum, 
the AS1411 applied was partially eluted (the flow volume 2-5 ml) before the imidazole 
addition.  This finding indicates that the PEG-Cu-AS1411 complex was dissociated in 
the presence of serum. The percentages of PEG-Cu-AS1411 complex dissociated after 1 
and 24 hr incubation in the serum were calculated to be 30 and 57, respectively. Figure 
4 shows the elution patterns of AS1411 from anion-exchange chromatographic column. 
The PEG-Cu-AS1411 complex was eluted in low salt concentration conditions 
compared with free AS1411. Figure 5 shows the number of PEG-Cu conjugated per one 
AS1411 molecule. The numbers of conjugated PEG-Cu per one AS1411 molecule 
became higher as the ratio of PEG-Cu / AS1411 increased. The number of PEG-Cu 
complexed per one AS1411 molecule was constant when the mixing molar ratio was 
more than 5. PEG-Cu prepared from high molecular weight PEG (Mw 40,000) showed 
one-third lower number of PEG-Cu complexed than that of low molecular weight PEG 
(Mw 5,000).  
 3.4. In vitro anti-tumor activity of PEG-Cu-AS1411 complexes 
Figure 6 shows the absorbance of cells cultured with or without 
PEG-Cu-AS1411 complexes. The absorbance reflects the mitochondria activity which is 
assumed to correspond to cell number. At 1 and 3 M of AS1411 concentration, the 
absorbance was as high as that of cells without any complexes, irrespective of the 
mixing molar ratio of PEG-Cu to AS1411. At 10 M of AS1411 concentration, the 
absorbance was low for any PEG-Cu-AS1411 complex. At the 5 and 7.5 M AS1411 
concentration, the absorbance increased with the increase in a mixing molar ratio.     
 
3.5. Tumor accumulation and blood circulation profiles of PEG-Cu-AS1411 
complexes  
Figure 7 shows the amount of AS1411-125I accumulated in the tumor site and 
the time profiles of blood circulation. The AS1411-125I modified with PEG-Cu was 
accumulated in the tumor site at significantly higher (1.5-2 fold) amounts than free 
AS1411-125I 6 and 24 hr after injection. In addition, the AS1411-125I modified was 
retained in the blood circulation for longer time periods. When evaluated, the 
distribution percentages in the organ of reticuloendothelial system (RES, liver and 
spleen) 24 hr after injection were 5.8 ± 0.03 and 0.20 ± 0.02 for free AS1411, 6.5 ± 0.28 
and 0.20 ± 0.06 for AS1411 complex with PEG-Cu of a molecular weight of 5,000, and 
6.5 ± 0.40 and 0.19 ± 0.04 for AS1411 complex with PEG-Cu of a molecular weight of 
40,000. 
Figure 8 shows the imaging photograph and intensity patterns of 
AS1411-Cy5.5 in the tumor site. The mice injected with PEG-Cu-AS1411-Cy5.5 
complex showed significantly stronger (1.5-2 fold) fluorescence at the tumor site than 
those injected with free AS1411-Cy5.5. 
 
3.6. In vivo anti-tumor therapeutic effect of PEG-Cu-AS1411 complexes  
Figure 9 shows the in vivo anti-tumor activity after intravenous injection of 
PBS, AS1411 alone or PEG-Cu-AS1411 complex to tumor-bearing mice. Both the 
tumor volume and weight of complex-injected mice were significantly smaller (10 and 
30% for tumor volume and weight, respectively) than those of mice injected with PBS 
or free AS1411. 
 
Discussion   
The present study demonstrates that AS1411 was complexed to PEG-NTA with 
Cu2+-coordination only by their simple mixing. The Cu2+-coordinated PEG modification 
enabled AS1411 to prolong the life-time in the blood circulation and enhance the tumor 
accumulation. It is highly conceivable that this in vivo fate of complexes contributed to 
their enhanced in vivo anti-tumor effect.  
It has been previously demonstrated that the body distribution profiles after 
intravenous injection of drug modified with a polymer by different methods (covalent 
bond [23] vs. metal coordination [24]) was similar to each other. Therefore, the 
PEGylation based on metal coordination is a simple and feasible method to actively 
change the body distribution of drugs. It was revealed that the percentages of 
PEG-Cu-AS1411 complex dissociated after 1 and 24 hr incubation in the serum were 30 
and 57, respectively (Figure 3). It is possible that the metal coordination bond was 
stable enough to allow the complex to circulate in the blood for modification of the 
body distribution. 
NTA was selected as the chelating residue of metal ions [25, 26], because it has 
been previously used to prepare a chelating residue-introduced PEG [13]. Copper ions 
(Cu2+ ions) were selected as the metal ions because of the high stability constant to NTA 
(Cu2+; 12.96) compared with another metal ions (Ca2+; 6.41, Mg2+; 5.46, Fe2+; 8.84, 
Ni2+; 11.54, Zn2+; 10.66). The NMR and chromatographic studies showed that the 
PEG-NTA had a chelating ability for Cu2+ ions (Figures 1 and 2). The number of Cu2+ 
coordinated per one PEG-NTA molecule was not influenced by the mixing molar ratio 
of PEG-NTA to Cu2+. Cu2+ ions were not bound to PEG-NHS without any NTA residue. 
Taken together, it is likely that Cu2+ ions was chelated to the NTA residue introduced to 
PEG in a theoretical fashion. In addition, it is shown that the 50% lethal dose (LD50) of 
is 87 mg/kg in a mouse. Since the body weight of mice used in this study is around 20 g, 
the LD50 for the mice is 1.74 mg. The amount of Cu2+ injected in this study is 
calculated to be 15.5 g, it is possible, therefore, that the toxicity of Cu2+ used in this 
study is quite low although the toxicity study should be done for the accurate 
evaluation. 
In this study, an aptamer was selected as a therapeutic drug [27]. Aptamer of 
nucleic acid has an artificial and short sequences of DNA or RNA and has a specific 
affinity for various materials. Thus, aptamer recoginizes biologically to a substance, 
similarly to antibody. In addition, it has many advantages over the antibody, such as the 
low cost, the shorter time or easer of synthesis, and the non-immunogenicity (called 
super antibody). The aptamer synthesis method is called “SELEX”[28] and various 
therapeutic aptamer has been synthesized [29, 30]. Various aptamers have been 
investigated to demonstrate their therapeutic activity of anti-tumor drugs [31, 32].  
In the anion-exchange chromatographic study, the elution peak of AS1411 
shifted to the direction to lower salt concentration fractions by mixing with PEG-Cu 
(Figure 4). This can be explained in terms of reduced negative charge of AS1411. It is 
conceivable that the negative charge of AS1411 was reduced by the complexing with 
PEG based on Cu2+ coordination, resulting in decreased interaction force between the 
AS1411 and the column. The number of PEG-Cu complexed per one AS1411 molecule 
was constant when the mixing molar ratio was more than 5 (Figure 5). When the ratio 
of PEG-Cu / AS1411 became higher, the frequency of PEG-Cu to encounter the AS1411 
increased. This increment would result in the enhanced ratio. However, the steric 
hinderance of PEG chains suppresses the Cu2+-coordinated conjugation. It is 
conceivable that the balance brings about the constant PEG-Cu/AS1411 ratio. PEG-Cu 
prepared from high molecular weight PEG (Mw 40,000) showed lower number of 
PEG-Cu complexed than that of low molecular weight PEG (Mw 5,000). It is likely that 
the high molecular weight and branched shape of PEG cause their larger steric 
hindrance than the linear and low Mw of PEG, which results in reduced complexation.    
The in vitro anti-tumor activity tended to increase as the AS1411 concentration 
become higher (Figure 6). It is reported that AS1411 itself can be recognized by 
nucleolin present on the surface of tumor cells [19, 33]. It is possible that the AS1411 
was covered by PEG-Cu with an increase in the PEG-Cu/AS1411 ratio, resulting in the 
reduced extent of AS1411 to be recognized. As the result, the anti-tumor activity of 
AS1411 would decrease. As lower amounts of AS1411, even though the covering effect 
by PEG-Cu conjugation was high, the anti-tumor activity was low. However, at the 
higher amounts, the AS1411 showed higher anti-tumor effects even although it was 
conjugated. The anti-tumor action of AS1411 is strong enough to suppress the in vitro 
growth of tumor cells. As the result, higher doses of AS1411 can biologically function 
the tumor cells for their growth suppression. The preliminary experiment demonstrates 
that the viability of A549 incubated with a scrambled DNA aptamer (20 M) or 
PEG-Cu (20, 100, and 400 M) was similar to that of cells without any treatment (data 
not shown). This result indicates that the DNA aptamer sequence is important to 
recognize a nucleorin expressed on the cell surface and that the Cu2+ coordinated does 
not affect the cell viability.   
The retention time of AS1411 in the blood circulation was prolonged by the 
Cu2+-coordinated PEG modification (Figure 7). The reason can be explained in terms of 
PEGylation effect. The PEGylation prevents not only the rapid renal clearance of drugs 
but also the uptake by the reticuloendothelial systems. In the present study, it was shown 
that the AS1411 showed a relatively longer circulation time in the blood (Figures 8) 
compared with the general aptamer [34], which well corresponds to other papers [35]. It 
is conceivable, therefore, that the prolonged life-time of AS1411 by the modification is 
due to the prevention of uptake by the reticuloendothelial systems or non-desired cells.  
It is likely that the prolonged blood circulation consequently enhanced the 
tumor accumulation (Figures 7 and 8). It is known that the coordination bond is 
weaken when the pH decreases (data not shown). In addition, the pH in the tumor tissue 
is lower than that of normal tissue [36]. It is possible that when the complex is 
accumulated in the tumor tissue, AS1411 is dissociated from the complex. We 
experimentally confirmed that the elution of AS1411 from Cu2+ chelating column was 
promoted at lower pHs. The AS1411 dissociated in the tumor tissue would be 
recognized by nucleolin on the tumor cell surface effectively, resulting in enhanced the 
anti-tumor activity. Therefore, the in vivo anti-tumor effect of AS1411 was enhanced by 
even although the activity of AS1411 was inhibited by the molecular covering through 
PEG-Cu complexation (Figure 6). 
In conclusion, the present study demonstrates that Cu2+ coordination enabled 
AS1411 to modify by the simple mixing of PEG. The AS1411 modified with PEG based 
on Cu2+ coordination was retained in the blood circulation for longer time periods, 
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Figure 1. Preparation of PEG-NTA by chemical coupling PEG-NHS with NTA. (A) 
Reaction scheme and (B) 1H-NMR spectra of NTA, PEG-NHS, and PEG-NTA. (C) The 
1H-NMR spectra of PEG-NTA enlarged.  
 
Figure 2. Gel permeation chromatographic patterns of Cu2+ ions and PEG-NTA 
mixtures ((A) and (C)) and the molar ratio of Cu2+ ions coordinated to the PEG-NTA 
((B) and (D)) after mixing PEG-NTA with Cu2+ ions at Cu2+ / PEG-NTA molar ratios of 
△1 (○), 3 ( ), 10 (●), and 50 (▲). (□) is control (PEG-NHS and Cu2+ ions). The Mw of 
PEG is 5,000 ((A) and (B)) or 40,000 ((C) and (D)). 
 
Figure 3. An elution pattern of free AS1411 from a Cu2+ ions chelating column in the 
absence (●) or presence of mouse serum incubated for 1 (▲) or 24 hr (■). 
 
Figure 4. Elution patterns of free AS1411 and PEG-Cu-AS1411 complexes from 
anion-exchange column at different salt concentrations. The PEG-Cu /AS1411 molar 
ratios are 0 (○) 1 (△), 5 (●), and 20 (▲). The Mw of PEG is 5,000 (A) or 40,000 (B). 
 
Figure 5. The number of PEG conjugated per one AS1411 molecule. The Mw of PEG is 
5,000 (□) or 40,000 (■) 
 
Figure 6. Viability of A549 cells after incubation with PEG-Cu-AS1411 complexes. 
Final concentration of AS1411 is 1 (○), 3 (△), 5 (●), 7.5 (▲) and 10 M (□). The 
Mw of PEG is 5,000 (A) or 40,000 (B). 
 
Figure 7. Time course of AS1411 accumulation in the tumor site (A) and blood 
circulation (B) after the intravenous injection into tumor-bearing nude mice with free 
AS1411 (□) and PEG-Cu-AS1411 complexes prepared from PEG with Mws of 5,000 
( ) and 40,000 (■). The amount of AS1411 injected is 50 mg per a mouse. *:p<0.05, 
significant against the accumulation amount of tumor-bearing mice injected with free 
AS1411 at the corresponding time. N.S.; not significant 
 
Figure 8. Time course of fluorescence imaging photograph (A) and intensity in the 
tumor site (B) after the intravenous injection into tumor-bearing nude mice with free 
AS1411 (□) and PEG-Cu-AS1411 complexes prepared from PEG with Mws of 5,000 
( ) and 40,000 (■). *:p<0.05, significant against the accumulation amount of 
tumor-bearing mice injected with free AS1411 at the corresponding time. N.S.; not 
significant 
 
Figure 9. Tumor volume (A) and tumor weight (B) of tumor-bearing mice after 
intravenous injection of PBS (○), free AS1411 (●), and PEG-Cu-AS1411 complexes 
△prepared from PEG with Mws of 5,000 ( ) and 40,000 (▲). Free AS1411 or the 
complexes were administered at a dose of 50 g /mice every 3 days. The tumor weight 
was measured 42 days after injection. *, p<0.05; significant against the tumor volume 
or tumor weight of tumor-bearing mice injected with free AS1411 at the corresponding 
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